Works Cited

1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.

2. Centers for Disease Control and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003–2010. MMWR. 2012;61(35):703-709.

3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.

4. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-e360.

5. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in U.S. adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med. 2007;167(22):2431-2436.

6. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46(2):280-286.

7. Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol. 2004;12(2):e267-e273.

8. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management: perspective of the Cohort Study of Medication Adherence among Older Adults (CoSMO).Med Clin North Am. 2009;93(3):753-769.

9. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105-2114.

10. Kuritzky L. White coat hypertension: addressing the 10 most important questions. Curr Cardiol Rep. 2012;14(6):678-683.

11. Banerjee D, Chung S, Wong EC, Wang EJ, Stafford RS, Palaniappan LP. Underdiagnosis of hypertension using electronic health records. Am J Hypertens. 2012;25(1):97-102.

12. Cuffe RL, Howard SC, Algra A, Warlow CP, Rothwell PM. Medium-term variability of blood pressure and potential underdiagnosis of hypertension in patients with previous transient ischemic attack or minor stroke. Stroke. 2006;37(11):2776-2783.

13. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-e526.

14. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 2009;302(4):401-411.

15. American Heart Association. High Blood Pressure and African Americans. Available at https://www.heart.org/en/health-topics/high-blood-pressure/why-high-blood-pressure-is-a-silent-killer/high-blood-pressure-and-african-americans. Last accessed August 14, 2019.

16. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci. 2014;348(2): 135-138.

17. Centers of Disease Control and Prevention. Hypertension-related mortality among Hispanic subpopulations—United States, 1995–2002. MMWR. 2006;55(7):177-180.

18. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466-472.

19. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension. 2000;36(5):780-789.

20. Hawkins K, Mittapally R, Chang J, Nahum GG, Gricar J. Burden of illness of hypertension among women using menopausal hormone therapy: a U.S. perspective. Curr Med Res Opin. 2010;26(12):2823-2832.

21. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.

22. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;356(9246):1955-1964.

23. Olafiranye O, Zizi F, Brimah P, et al. Management of hypertension among patients with coronary heart disease. Int J Hypertens. 2011;2011:653903.

24. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139(9):761-776.

25. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med. 1988;108(1):7-13.

26. Rheeder P, Stolk RP, Mosterd A, Pols HA, Hofman A, Grobbee DE. Insulin resistance syndrome and left ventricular mass in an elderly population (the Rotterdam study). Am J Cardiol. 1999;84(2):233-236.

27. DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61(3):556-560.

28. Armitage JA, Burke SL, Prior LJ, et al. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension. 2012;60(1):163-171.

29. Xiong XQ, Chen WW, Han Y, et al. Enhanced adipose afferent reflex contributes to sympathetic activation in diet-induced obesity hypertension. Hypertension. 2012;60(5):1280-1286.

30. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132-140.

31. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10);2449-2460.

32. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500-507.

33. Alexander MR. Hypertension. Available at https://emedicine.medscape.com/article/241381-overview#a3. Last accessed August 14, 2019.

34. Caillon A, Schiffrin EL. Role of inflammation and immunity in hypertension? Recent epidemiological, laboratory, and clinical evidence. Curr Hypertens Rep. 2016;18(3):21.

35. Rodríguez-IB, Pons H, Quiroz Y, Johnson RJ. The immunological basis of hypertension. Am J Hypertens. 2014;27(11):1327-1337.

36. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434-2506.

37. Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012;11(12):1039-1047.

38. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hypertens (Greenwich). 2000;2(5):324-330.

39. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.

40. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. Circulation. 1997;96(1):308-315.

41. Li Y, Wei FF, Wang S, Cheng YB, Wang JG. Cardiovascular risks associated with diastolic blood pressure and isolated diastolic hypertension. Curr Hypertens Rep. 2014;16(11):489.

42. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278(3):212-216.

43. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.

44. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282(6):539-546.

45. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood pressure monitoring: task force V: white-coat hypertension. Blood Press Monit. 1999;4(6):333-341.

46. Michigan Medicine. University of Michigan Health System. Essential Hypertension. Available at http://www.med.umich.edu/ 1info/FHP/practiceguides/newhtn/htn.pdf. Last accessed August 14, 2019.

47. Muxfeldt ES, Fiszman R, de Souza F, Viegas B, Oliveira FC, Salles GF. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension. 2012;59(2):384-389.

48. Bombelli M, Grassi G, Mancia G, Seravalle G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol. 2011;8(12):686-693.

49. Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med. 2004;15(6):348-357.

50. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57(6):1076-1080.

51. Carey RM. Resistant hypertension. Hypertension. 2013;61(4):746-750.

52. Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012;60(3):653-658.

53. Václavík J, Sedláck R, Plachý, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069-1075.

54. Polimeni A, Curcio A, Indolfi C. Renal sympathetic denervation for treating resistant hypertension. Circ J. 2013;77(4):857-863.

55. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124(18):1945-1955.

56. Karns AD, Bral JM, Hartman D, Peppard T, Schumacher C. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertension. 2013;15(3):186-192.

57. Park CG, Lee JY. The significance of the J-curve in hypertension and coronary artery diseases. Korean Circ J. 2011;41(7):349-353.

58. Kaplan NM. The diastolic J curve: alive and threatening. Hypertension. 2011;58(5):751-753.

59. Filippone EJ , Foy A. The J-curve revisited: a therapeutic dilemma. Cardiol Rev. 2012;20(5):253-258.

60. Cunnane RT, Bakris GL. Hypertensive goals in patients with coronary artery disease. Curr Cardiol Rep. 2012;14(6):667-672.

61. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009;3:CD004349.

62. American Diabetes Association. Standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S1-S193.

63. Whelton PK, Carey RM, Aranow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.

64. U.S. Preventive Services Task Force. Final Recommendation Statement: High Blood Pressure in Adults: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/high-blood-pressure-in-adults-screening. Last accessed August 14, 2019.

65. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting. Available at https://www.healthquality.va.gov/hypertension/htn04_pdf1.pdf. Last accessed August 14, 2019.

66. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288(15):1882-1888.

67. Eckel RH, Jakicic JM, Ard JD, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129 (25 Suppl 2):S76-S99.

68. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure. Arch Intern Med. 1997;157(6):657-667.

69. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35(2):544-549.

70. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2000;35(3):838-843.

71. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials.Ann Intern Med. 2002;136(7):493-503.

72. Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: an update. Sports Med. 2000;30(3):193-206.

73. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473.

74. Pescatello LS, Franklin BA, Fagard R, et al. Exercise and hypertension. Med Sci Sport Exer. 2004;36(3):533-553.

75. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38(5):1112-1117.

76. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10.

77. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135(12):1019-1028.

78. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension. 2000;35(4):858-863.

79. Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep. 2007;9(6):520-528.

80. Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension. 1999;33(1 Opt 2):586-590.

81. Academy of Nutrition and Dietetics. Hypertension (HTN) Guideline (2015): 2015 Hypertension Evidence-Based Nutrition Practice Guidelines. Available at https://www.andeal.org/topic.cfm?menu=5285&cat=5582. Last accessed August 14, 2019.

82. National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure with DASH. DASH Eating Plan: Lower Your Blood Pressure. Available at https://www.nhlbi.nih.gov/files/docs/public/heart/hbp_low.pdf. Last accessed August 14, 2019.

83. Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170(2):126-135.

84. Forman JP, Scheven L de Jong PE, Bakker SJ, Curhan GC, Gansevoort RT. Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension. Circulation. 2012;125(25):3108-3116.

85. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289(16):2083-2093.

86. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45(5):637-651.

87. Okonta NR. Does yoga therapy reduce blood pressure in patients with hypertension? An integrative review. Holist Nurs Pract. 2012;26(3):137-141.

88. Subramanian H, Soudarssanane MB, Jayalakshmy R, et al. Non-pharmacological interventions in hypertension: a community-based cross-over randomized controlled trial. Indian J Community Med. 2011;36(3):191-196.

89. Kim HM, Cho SY, Park SU, et al. Can acupuncture affect the circadian rhythm of blood pressure? A randomized, double-blind, controlled trial. J Altern Complement Med. 2012;18(10):918-923.

90. Chen NY, Zhou Y, Dong Q, Zhou CX. Observation on therapeutic effect of acupuncture in the treatment of German hypertension patients. Zhen Ci Yan Liu. 2010;35(6):462-466.

91. Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults in the United States. Available at https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking. Last accessed August 14, 2019.

92. Bailey AM, Macaulay T. Pharmacologic approaches to smoking cessation. Orthopedics. 2012;35(6):505-511.

93. Ge Z, Hao Y, Cao J, et al. Does cigarette smoking exacerbate the effect of blood pressure on the risk of cardiovascular and all-cause mortality among hypertensive patients? J Hypertens. 2012;30(12):2307-2013.

94. Rodriguez D, Weighell W, Edel A, et al. Potent anti-hypertensive actions of dietary flaxseed in patients with peripheral arterial disease in the Flaxpad Trial. Circulation. 2012;126:A12080.

95. Rasmussen CB, Glisson JK, Minor DS. Dietary supplements and hypertension: potential benefits and precautions. J Clin Hypertens(Greenwich). 2012;14(7):467-471.

96. Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme for Q10 for primary hypertension. Cochrane Database Syst Rev. 2016;3:CD007435.

97. Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20(1):107-120.

98. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension. 2013;61(6):1360-1383.

99. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens (Greenwich). 2011;13(3):146-154.

100. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591-603.

101. Baguet JP. Out-of-office blood pressure: from measurement to control. Int Blood Press Control. 2012;5:27-34.

102. U.S. Food and Drug Administration. Tekturna: Highlights of Prescribing Information [Package Insert]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021985s012lbl.pdf. Last accessed August 14, 2019.

103. U.S. Food and Drug Administration. Edarbi: Highlights of Prescribing Information [Package Insert]. Available at https://www.edarbi.com/media/pdf/EDARBI-PI.pdf. Last accessed August 14, 2019.

104. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1): 3-15.

105. LexiComp Online. Available at http://online.lexi.com. Last accessed August 14, 2019.

106. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330(26):1852-1857.

107. Sood N, Reinhart KM, Baker WL. Combination therapy for the management of hypertension: a review of the evidence. Am J Health-Syst Pharm. 2010;67(11):885-894.

108. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300.

109. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499-2506.

110. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining blood pressure goals in hypertensive patients. Curr Med Res Opin. 2008;24(8):2389-2401.

111. Bakris GL, Sowers JR; American Society of Hypertension Writing Group. ASH position paper: treatment of hypertension in patients with diabetes—an update. J Clin Hypertens. 2008;10(9):707-713.

112. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide versus chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12)1229:e1-1229.e10.

113. Germino FW. Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?Curr Cardiol Rep. 2012;14(6):673-677.

114. Philipp T, Smith TR, Galzer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563-580.

115. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, controlled, 8-week factorial efficacy and safety study.Clin Ther. 2008;30(4):587-604.

116. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.

117. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.

118. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213.

119. Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16(7):544-548.

120. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364(9446):1684-1689.

121. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545-1553.

122. Bradley HA, Wiysonge CS, Volmnik JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24(11):2131-2141.

123. Cruickshank JM. The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol. 2017;956:149-166.

124. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.

125. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1-S290.

126. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Available at https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Blood-Pressure-Guideline-English.pdf. Last accessed August 14, 2019.

127. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus Document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57(20):2037-2114.

128. Hoyer J. Non-pharmacological and pharmacological treatment of arterial hypertension: current situation. Herz. 2012;37(7):728-734.

129. Chobanian AV. Impact of nonadherence to antihypertensive therapy. Circulation. 2009;120(16):1558-1560.

130. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-1152.

131. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs.J Hypertens. 2005;23(11):2101-2107.

132. Hill MN, Miller NH, DeGeest S, et al. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12(10):757-764.

133. Chobanian AV. The hypertension paradox—more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361(9): 878-887.

134. De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.

135. Vawter L, Tong X, Gemilyan M, Yoon PW. Barriers to antihypertensive medication among adults—United States, 2005. J Clin Hypertens (Greenwich). 2008;10(12):922-929.

136. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-1196.

137. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich). 2010;12(1):40-46.

138. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care?Arch Intern Med. 2004;164(7):722-732.

139. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.

140. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834.

141. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351.

142. Rose AJ, Berlowitz DR, Orner MB, Kressin NR. Understanding uncontrolled hypertension: is it the patient or the provider?J Clin Hypertens. 2007;9(12):937-943.

143. Zolnierek KB, DiMatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826-834.

144. Martin KD, Roter DL, Beach MC, Carson KA, Cooper LA. Physician communication behaviors and trust among black and white patients with hypertension. Med Care. 2013;51(2):151-157.

145. Eamranond PP, Patel KV, Legedza AT, Marcantonio ER, Leveille SG. The association of language with prevalence of undiagnosed hypertension among older Mexican Americans. Ethn Dis. 2007;17(4):699-706.

146. Karliner L, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.

147. Navar-Boggan AM, Boggan JC, Stafford JA, Muhbaier LH, McCarver C, Peterson ED. Hypertension control among patients followed by cardiologists. Circ Cardiovasc Qual Outcomes. 2012;5(3):352-357.

148. Odedosu T, Schoenthaler A, Vieira DL, Agyemang C, Ogedegbe G. Overcoming barriers to hypertension control in African Americans. Cleve Clin J Med. 2012;79(1):46-56.

149. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525-541

150. Howard G, Lackland DT, Kleindorfer DO, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med. 2013;173(1):46-51.

151. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780-800.

152. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117-1124.

153. Ferdinand KC. A compendium of antihypertensive therapy. J Clin Hypertens (Greenwich). 2011;13(9):636-638.

154. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172(22):1739-1744.

155. Reynolds K, Shimbo D, Bowling CB, et al. OS 16-06 risk factors for serious fall injuries following initiation of antihypertensive medication. J Hypertens. 2016;34(Suppl 1):e219-e220.

156. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.J Am Coll Cardiol. 2015;65(18):1998-2038.

Evidence-Based Practice Recommendations Citations

1. Diagnosis and Management of Hypertension Working Group. VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014. Available at https://www.healthquality.va.gov/guidelines/CD/htn/VADoDCPGHTN2014.pdf. Last accessed September 18, 2019.


Copyright © 2019 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.